Franklin Resources Inc Precision Biosciences Inc Transaction History

Franklin Resources Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.34 - $0.69 $5,065 - $10,279	-14,898 Reduced 20.75%	56,909 $19,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $1,126 - $37,658	923 Added 1.3%	71,807 $93,000
Q2 2022 Aug 11, 2022	BUY	$1.15 - $3.34 $52,278 - $151,836	45,460 Added 178.81%	70,884 $113,000
Q4 2021 Feb 11, 2022	BUY	$7.4 - $11.66 $188,137 - $296,443	25,424 New	25,424 $188,000
Q3 2020 Nov 12, 2020	SELL	$4.65 - $8.73 $4.79 Million - $8.99 Million	-1,030,156 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$4.66 - $8.7 $358,726 - $669,726	-76,980 Reduced 6.95%	1,030,156 $8.52 Million
Q1 2020 May 13, 2020	SELL	$5.05 - $15.01 $539,294 - $1.6 Million	-106,791 Reduced 8.8%	1,107,136 $6.68 Million
Q4 2019 Feb 12, 2020	SELL	$6.32 - $19.66 $3.43 Million - $10.7 Million	-542,200 Reduced 30.87%	1,213,927 $16.9 Million
Q3 2019 Nov 14, 2019	SELL	$8.03 - $14.82 $3.31 Million - $6.12 Million	-412,720 Reduced 19.03%	1,756,127 $14.7 Million
Q2 2019 Aug 14, 2019	BUY	$11.88 - $16.94 $11.5 Million - $16.4 Million	968,727 Added 80.72%	2,168,847 $27.7 Million
Q1 2019 May 14, 2019	BUY	$17.44 - $17.95 $20.9 Million - $21.5 Million	1,200,120 New	1,200,120 $21.5 Million

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $657M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.